Supplemental Tables for ""FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer patients: a propensity score-based analysis," by Chiara Cremolini et al.

Supplemental Table S1. Propensity score matched sensitivity analysis for activity according to treatment.

Treatment	Response (CR+PR)			Clinical benefit (CR+PR+SD)		
	N (%)	OR (95% CI)*	*P* value*	*N* (%)	OR (95% CI)*	*P* value*
FOLFOX-P (*N*=118)	96 (81)	ref	0.11	112 (95)	ref	0.67
FOLFOXIRI-B (*N*=118)	87 (74)	0.92 (0.84-1.02)		113 (96)	1.01 (0.97-1.05)	
*Conditional logistic regression Wald test						
Abbreviations. CR: complete response; PR: partial response; SD: disease stabilization; OR: odds ratio; CI: confidence interval; B: bevacizumab; P: panitumumab.						

Supplemental Table S2. Propensity score adjusted analysis of secondary resections with curative intent according to treatment.

	Total (*N*=317) N (%)	FOLFOX-P (*N*=185) N (%)	FOLFOXIRI-B (*N*=132) N (%)	Raw P value*	PS-adjusted *P Value**
Secondary resection	63 (20)	34 (18)	29 (22)	0.43	0.51
*Logistic regression Wald test					
Abbreviations. P: panitumumab; B: bevacizumab; PS: propensity score.					

Supplemental Table S3. Propensity score matched sensitivity analysis of secondary resections with curative intent according to treatment.

	Total (*N*=248) N (%)	FOLFOX-P (*N*=124) N (%)	FOLFOXIRI-B (*N*=124) N (%)	*P* value*
Secondary resection	54 (22)	26 (21)	28 (23)	0.79

*Conditional logistic regression Wald test

Abbreviations. P: panitumumab; B: bevacizumab.

Supplemental Table S4. Propensity score matched sensitivity analysis of the incidence of chemotherapy-related adverse events of grade 3 or 4 according to treatment.

Grade 3/4 Adverse events	FOLFOX-P (*N*=124) *N* (%)	FOLFOXIRI-B (*N*=124) *N* (%)	*P* value*
All	63 (51)	73 (59)	0.39
Neutropenia	37 (30)	59 (48)	0.03
Febrile Neutropenia	4 (3)	8 (6)	0.26
Anemia	4 (3)	5 (4)	0.74
Thrombocytopenia	5 (4)	3 (2)	0.48
Nausea	4 (3)	6 (5)	0.53
Vomiting	2 (2)	5 (4)	0.27
Stomatitis/Oral mucositis	11 (9)	8 (6)	0.49
Diarrhea	16 (13)	15 (12)	0.86
Peripheral Neuropathy	6 (5)	4 (3)	0.53

*Conditional logistic regression Wald test

Abbreviations. P: panitumumab; B: bevacizumab.